The dual effects of MOGAT2 inhibitors on lowering triglycerides and causing weight loss has great potential in treating MASLD/MASH, as obesity is a major risk factor in driving the progression of MASLD/MASH (26, 81, 82). The gene discussed is MOGAT2; the disease is metabolic dysfunction-associated steatohepatitis.